The real world experience with single agent ibrutinib in relapsed/refractory cll

Chronic lymphocytic leukemia (CLL) is characterized by progressive accumulation of mature-appearing monoclonal B lymphocytes and is the most prevalent form of leukemia in the Western world.1 Although chemoimmunotherapy is still a reasonable treatment option for standard-risk/fit patients, the management of high-risk patients presenting with del17p/p53mut or unmutated IGHV (uIGHV) has been an unmet medical need in achieving long-term survival. The emergence of novel agents targeting the B-cell receptor pathway (ibrutinib, acalubritinib, idealisib) and BCL-2 (venetoclax) has significantly changed the therapeutic landscape of CLL in both upfront and relapsed/refractory settings.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 14, 2021 Category: Hematology Authors: Seval Akpinar, Mehmet Hilmi Dogu, Serhat Celik, Omer Ekinci, Ipek Yonal Hindilerden, Mehmet Sinan Dal, Eren Arslan Davulcu, Atakan Tekinalp, Fehmi Hindilerden, Busra Gokce Ozcan, Tuba Hacibekiroglu, Mehmet Ali Erkurt, Metin Bagci, Sinem Namdaroglu, Gulten Source Type: research